Community Practice Connections™: Focused Takeaways from the Ophthalmology Times® EyeCon 2021
February 22, 2022
February 22, 2023
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Physicians’ Education Resource®, LLC.
This activity is supported by educational grants from AbbVie Inc., Alcon Vision, LLC, Genentech, a member of the Roche Group, Johnson & Johnson Surgical Vision, Inc., and Santen.
- Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)™
- Nurses — 1.5 Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation.
This educational program is directed toward general ophthalmologists and ophthalmology subspecialists who treat patients with eye disorders in clinical settings. Other health care professionals interested in the management of patients with eye disorders are also invited to attend.
Competence to manage common and unusual eye conditions is essential for the ophthalmologist, because many ocular diseases negatively impact quality of life and, in some cases, lead to loss of vision if not managed appropriately. A number of new and emerging procedures and therapies are changing the way ocular diseases are treated and can lead to better patient outcomes.
This Community Practice Connections™ program provides an in-depth review of some of the key highlights from the inaugural Ophthalmology Times® EyeCon 2021 virtual conference, held in December 2021. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on new and emerging developments in the field of eye health, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.
Upon completion of this activity, participants should be better able to:
- Implement diagnostic approaches to correctly identify early presentations of both common and rare ocular diseases
- Demonstrate the ability to apply clinical trial data to optimize patient treatment in the eye-care setting
- Explain efficacy and trial data from recent clinical trials of investigational agents
- Identify the most appropriate strategies to improve vision outcomes in patients with common and unusual disease processes
Peter J. McDonnell, MD
William Holland Wilmer Professor of Ophthalmology
Johns Hopkins University School of Medicine
Director, Wilmer Eye Institute
Oluwatosin U. Smith, MD
Glaucoma Associates of Texas
Department of Ophthalmology
University of Texas Southwestern
David M. Katz, MD
Clinical Associate Professor, Ophthalmology and Neurology
Howard University Hospital
Clinical Assistant Professor, Ophthalmology
Georgetown University Hospital
Arshad M. Khanani, MD, MA
Director of Clinical Research and Fellowship
Sierra Eye Associates
Clinical Associate Professor
University of Nevada
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.
- Peter J. McDonnell, MD
- Board of directors: Aerie Pharmaceuticals
- Oluwatosin U. Smith, MD
- Grant/Research Support: Allergan, Inc., Santen Pharmaceutical Co. Ltd., iStar Medical, AGS
- Consultant: Glaukos, Alcon, Allergan, Aerie Pharmaceuticals, Bausch + Lomb, Santen Pharmaceutical Co. Ltd, New World Medical
- Speaker’s Bureau: Allergan, Inc., Aerie Pharmaceuticals, Bausch + Lomb
- Shareholder: Nova Eye Medical
David M. Katz, MD, has no relevant financial relationships with ineligible companies.
- Arshad M. Khanani, MD, MA
- Consultant: Genentech, Regenxbio, Inc., Oxurion, Opthea, Unity Biotechnology, Kodiak Sciences, Inc
- Speaker’s Bureau: Genentech, Regenxbio, Inc., Oxurion, Opthea, Unity Biotechnology, Kodiak Sciences, Inc.
- Shareholder: Genentech
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Instructions for Participation and Credit
- Complete the activity (including pre- and post-activity assessments).
- Answer the evaluation questions.
- Request credit using the drop-down menu.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.